Yahoo · Oct 9, 2026
Charles River Laboratories Schedules Third-Quarter 2026 Earnings Release and Conference Call
WILMINGTON, Mass., October 09, 2026--Charles River Laboratories Schedules Third-Quarter 2026 Earnings Release and Conference Call
NASDAQ · CRL
Charles River Laboratories International, Inc.
Healthcare · Medical - Diagnostics & Research
$302.00
Up+$2.98 (+1.00%)
Updated Oct 15, 2026, 12:49 PM
SID Score
6.5/10
Composite research score
Smart Money
58/100
Neutral
- Market cap
- 9.57B
- P/E ratio
- -137.99
- Dividend yield
- 0.00%
- 52-week range
- $146.20 – $333.30
- Volume
- 941.77K
- Avg. volume
- 1.03M
Price performance · CRL
CRL price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 14, 2026
CRL closed at $302.00 after 21 trading sessions, up 10.46% for the selected period.
- Last close
- $302.00
- Period change
- +10.46%
- Period low
- $273.41
- Period high
- $310.77
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 14, 2026 | $297.53 | $310.53 | $296.00 | $302.00 | 941.77K |
| Oct 13, 2026 | $301.00 | $302.77 | $295.15 | $299.02 | 753.33K |
| Oct 12, 2026 | $301.80 | $303.10 | $299.2718 | $301.86 | 543.77K |
| Oct 9, 2026 | $294.60 | $305.205 | $294.60 | $301.79 | 679.86K |
| Oct 8, 2026 | $297.01 | $298.27 | $288.425 | $298.00 | 1.18M |
| Oct 7, 2026 | $303.38 | $305.18 | $294.28 | $300.30 | 1.24M |
| Oct 6, 2026 | $319.80 | $333.295 | $300.01 | $304.96 | 1.92M |
| Oct 5, 2026 | $292.05 | $312.26 | $292.02 | $310.77 | 1.31M |
| Oct 2, 2026 | $287.91 | $290.6125 | $285.75 | $290.19 | 445.52K |
| Oct 1, 2026 | $291.86 | $297.00 | $284.6106 | $286.83 | 823.07K |
| Sep 30, 2026 | $296.97 | $298.9839 | $293.455 | $295.01 | 799.36K |
| Sep 29, 2026 | $294.71 | $298.20 | $289.38 | $295.96 | 661.45K |
| Sep 28, 2026 | $289.13 | $296.8825 | $289.13 | $294.59 | 901.74K |
| Sep 25, 2026 | $293.19 | $295.2276 | $287.2348 | $292.84 | 838.26K |
| Sep 24, 2026 | $277.00 | $298.40 | $276.95 | $294.44 | 1.59M |
| Sep 23, 2026 | $283.85 | $291.09 | $276.64 | $277.33 | 1.59M |
| Sep 22, 2026 | $280.19 | $290.11 | $277.41 | $285.11 | 1.14M |
| Sep 21, 2026 | $279.37 | $281.63 | $275.88 | $279.01 | 952.93K |
| Sep 18, 2026 | $281.26 | $282.995 | $276.00 | $278.06 | 1.48M |
| Sep 17, 2026 | $280.11 | $285.5775 | $274.40 | $281.67 | 809.84K |
| Sep 16, 2026 | $272.78 | $282.905 | $270.88 | $273.41 | 1.01M |
Latest CRL news
The latest Smart Investors Daily articles mentioning CRL.
Stock researchCompany · Overview
Company
Market Activity
Research & News
CRL research
Overview
Company profile and research snapshot.
Company profile
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $191.50
- Implied upside
- —
- Analysts
- 22
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 13, 2026 | Morgan Stanley | Overweight | — |
| Sep 30, 2026 | UBS | Buy | — |
| Sep 28, 2026 | Jefferies | Buy | — |
| Sep 25, 2026 | Deutsche Bank | Buy | — |
| Sep 25, 2026 | Evercore ISI Group | Outperform | — |
News briefing
No generated briefing is available yet.
Yahoo · Oct 6, 2026
Charles River and Autolomous Partner to Transform Laboratory Execution Systems
WILMINGTON, Mass. & LONDON, October 06, 2026--Charles River Laboratories International, Inc. (NYSE: CRL) and Autolomous today announced the launch of Apollo Orchestrate™, a new capability within Charles River's Apollo® platform that connects and digitizes laboratory execution, built on Autolomous's autoloMATE® digital Laboratory Execution System (LES). The launch demonstrates continued progress on Charles River's strategic commitment to modernize and digitize laboratory workflows. Apollo® Orches
Benzinga · Oct 6, 2026
Charles River Laboratories and Autolomous Launch Apollo Orchestrate To Digitize Laboratory Execution Through autoloMATE Integration
Partnership reinforces continued investment in digitization, automation, and client-facing transparencyCharles River Laboratories International, Inc. (NYSE:CRL) and Autolomous today announced the launch of Apollo
ChartMill · Oct 5, 2026
Uncover the latest developments among S&P500 stocks in today's session.
Stay updated with the movement of S&P500 stocks in today's session. Discover which S&P500 stocks are making waves on Monday.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
